Systematic review quantifies metabolic rebound after stopping GLP-1 drugs: weight regain is near-universal but variable | Research

The takeaway

Meta-analysis quantifies metabolic rebound after GLP-1RA discontinuation: near-universal weight regain but variable rate, with HbA1c and cardiovascular parameters also worsening, though residual benefit may persist for some outcomes.

Rebound quantified
Near-universal weight regain occurs after stopping GLP-1 drugs, with metabolic deterioration—but the rate varies and some benefits may persist, supporting planned transitions

What the researchers found

Weight regain: near-universal but variable rate. HbA1c: worsened. Cardiovascular parameters: deteriorated. Some residual benefit: may persist. Modifiers identified: treatment duration, lifestyle, individual factors. Comprehensive quantification of rebound.

Why it matters

Millions will eventually stop GLP-1 drugs (cost, shortage, personal choice). Quantifying what happens—and what modifies rebound—helps plan transitional care and manage expectations.

How the study worked

Systematic review and meta-analysis of GLP-1RA discontinuation studies in obesity, T2DM, and T1DM.

What this study cannot tell us

Heterogeneous discontinuation studies. Variable follow-up durations. No standardized rebound definition. Some studies small.

How to read the evidence

Systematic review and meta-analysis of available discontinuation data. Comprehensive quantification.

When this study was published

Published in 2025.

The bigger picture

Metabolic rebound after GLP-1 drug cessation is the Achilles heel of current obesity pharmacotherapy. This quantification enables evidence-based discontinuation planning and drives research into anti-rebound strategies.

Questions still open

How long do residual benefits persist after stopping?
Can lifestyle intensification prevent rebound?
Should GLP-1 drugs be lifelong or is tapering viable?

Common questions

What happens when you stop GLP-1 drugs?

Weight regain is nearly universal, though the amount and speed vary. Blood sugar control worsens, and cardiovascular risk factors deteriorate. However, some benefits may persist partially. The rebound is not necessarily immediate—planning a gradual transition with lifestyle support can help minimize it.

Should GLP-1 drugs be taken forever?

This meta-analysis suggests that stopping leads to metabolic rebound, supporting long-term or lifelong use for many patients—consistent with treating obesity as a chronic disease. However, factors like treatment duration and lifestyle changes may modify the rebound, and some benefits appear to persist after stopping.

Read the original research

Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.

EClinicalMedicine, 90, 103680

View on PubMed ↗Publisher’s paper ↗

Citation

Tzang, Chih-Chen; Wu, Pei-Hsun; Luo, Chiao-An; Chen, Zi-Ting; Lee, Yi-Ting; Huang, Ewen Shengyao; Kang, Yuan-Fu; Lin, Wei-Chen; Tzang, Bor-Show; Hsu, Tsai-Ching. (2025). Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.. EClinicalMedicine, 90, 103680. https://doi.org/10.1016/j.eclinm.2025.103680